Evidence tier: B — investigational (positive Phase 2/3 topline; not yet FDA-approved).
Here's the twist that makes this one interesting: VDPHL01 isn't a new molecule at all. It's minoxidil — the same drug in your topical foam and in the off-label pills thousands of people already take. The innovation is how it's delivered.
Let me explain why that's a bigger deal than it sounds.
What VDPHL01 is
VDPHL01, from Veradermics, is a proprietary extended-release oral minoxidil tablet being developed for pattern hair loss in both men and women. It's non-hormonal (nothing to do with DHT or finasteride's mechanism), and it's aiming for something no one has pulled off in almost three decades: FDA approval as an oral pill for hair loss. [1][2]
How it works — and why "extended-release" matters
Minoxidil grows hair by acting as a potassium-channel opener that pushes follicles into the growth (anagen) phase. That part is well established — it's a Tier-A mechanism.
The catch with regular oral minoxidil (taken off-label today) is that it hits your system in a spike: absorb fast, peak, fade. That spike is tied to the side effects people worry about — the lightheadedness, the fluid retention, the racing heart.
Here's the idea behind VDPHL01: smooth the curve. By releasing the drug slowly over time instead of all at once, it aims to deliver steady exposure to the follicle while keeping the peaks — and hopefully the side effects — lower. Think of it like the difference between slamming an espresso and sipping it over an hour. Same caffeine, very different jolt.
That's the whole bet: same proven drug, gentler, standardized, and in a properly-tested, regulated pill instead of splitting BPH tablets off-label.
What the trials actually show
In 2026, Veradermics reported positive topline results from Part A of its Phase 2/3 "302" trial in over 500 men (519 randomized) with mild-to-moderate pattern hair loss, comparing VDPHL01 8.5 mg once daily and twice daily against placebo. [1][3]
Reading it the way we read every trial on the pipeline tracker:
- It met all primary and key secondary endpoints with high statistical significance in both dose arms — a genuinely strong topline. [1]
- On safety, it was generally well tolerated through Month 6, with adverse-event rates similar to placebo, lower discontinuation than placebo, and — notably — no treatment-related serious adverse events and no cardiac adverse events of special interest reported in the study. [1][3]
- Still to come: a second Phase 3 male trial ("304") with topline results expected in the second half of 2026, plus a female pattern hair loss trial ("306"). [1]
Bottom line on the data: strong, late-stage, and — because it's a known drug in a better delivery — arguably lower-risk than a brand-new molecule. But "positive topline" is not "approved," and the full published data and an FDA decision are what will settle it.
Realistic expectations
- If approved, VDPHL01 would mainly be a more predictable, regulated version of a treatment people already use — attractive to those who want oral minoxidil's benefits without splitting off-label BPH pills or guessing at dose.
- It's a growth stimulator, so like every AGA treatment it works while you take it, and it doesn't touch the DHT side of the equation — many people would still pair a growth driver with a DHT approach (finasteride/dutasteride) under a doctor's guidance.
- Being studied in women too is a real gap-filler — options formally tested for female pattern hair loss are thin.
How I'd think about it
I'm on topical minoxidil myself, and oral minoxidil is one of those things I've researched carefully rather than jumped into — precisely because of the systemic side-effect question. What makes VDPHL01 appealing to me as a concept is that it attacks that exact concern with the delivery mechanism, and it does so inside a real regulatory trial instead of off-label guesswork. If it lands, I'd want to see the full published safety data and, as always, baseline photos in the tracker before and during — because "well tolerated in a trial" still has to prove out on your own head and your own heart.
FAQ
Is VDPHL01 available yet? No. As of mid-2026 it's investigational — positive Phase 2/3 topline data, with more trials reading out and no FDA approval yet. [1]
How is VDPHL01 different from regular oral minoxidil? Same active drug (minoxidil), different delivery. VDPHL01 is an extended-release tablet designed to smooth systemic exposure, aiming for steady efficacy with fewer peak-related side effects — and it's being formally tested for FDA approval rather than used off-label. [2]
Could VDPHL01 be the first oral hair-loss pill approved by the FDA? Veradermics believes its data could position VDPHL01 to become the first FDA-approved oral pill for pattern hair loss in nearly 30 years — but approval isn't guaranteed and timelines can shift. [1][2]
Is it for women too? Yes — a female pattern hair loss trial is part of the program, which is notable given how few options are formally studied in women. [1]
Sources
- Veradermics — Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 '302' Clinical Trial (Apr 2026). https://ir.veradermics.com/news-releases/news-release-details/veradermics-oral-vdphl01-achieved-early-consistent-and-robust
- Dermatology Times — Veradermics Launches Phase 2/3 Trial for VDPHL01, a Potential First FDA-Approved Oral Treatment. https://www.dermatologytimes.com/view/veradermics-launches-phase-2-3-trial-for-vdphl01-a-potential-first-fda-approved-oral-treatment-for-fphl
- The Dermatology Digest — Veradermics' Oral VDPHL01 Achieves Early, Consistent, and Robust Hair Growth in Phase 2/3 Study. https://thedermdigest.com/veradermics-oral-vdphl01-achieves-early-consistent-and-robust-hair-growth-in-phase-2-3-study-of-male-pattern-hair-loss/
Investigational drug; not medical advice. See our editorial standards and medical disclaimer. Refresh when Study '304' reads out and on any FDA decision.